Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across ...
New Atlas

New approach shields memory from brain cancer radiotherapy

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...
American Council on Science and Health

Lying Eyes” Go Bionic: How Technology Is Rewriting Human Vision

For decades, treatments for macular degeneration have focused on slowing, not restoring vision loss. A new retinal implant is ...
Pharmabiz

Complement Therapeutics receives US FDA clearance to begin Opti-GAIN phase I/II trial of CTx001 in patients with GA secondary to AMD

Complement Therapeutics receives US FDA clearance to begin Opti-GAIN phase I/II trial of CTx001 in patients with GA secondary to AMD: Munich, Germany Thursday, October 9, 2025, 11 ...

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many ...

Study identifies new approach to protect the brain during radiation therapy

While tremendous relief comes from successfully battling cancer, survivors can also experience cognitive impairments caused ...
Medindia

Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD

Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) ...
KXAN

Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD

CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria ...

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.18, along with a high estimate of $52.00 and a low estimate of $18.00. This upward ...

Apellis Pharmaceuticals, Inc.: New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN ...

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of pat ...